pcDNA™3.1 Directional TOPO™ Expression Kit
Product Image
Invitrogen™

pcDNA™3.1 Directional TOPO™ Expression Kit

El kit de expresión pcDNA™3.1 direccional TOPO™ utiliza el vector pcDNA3.1D/V5-His-TOPO™ linealizado y activado por la topoisomerasa I para lograrMás información
Have Questions?
Cambiar vistabuttonViewtableView
Número de catálogoCantidad
K49004040 reacciones
K49000120 reacciones
Número de catálogo K490040
Precio (MXN)
-
Cantidad:
40 reacciones
El kit de expresión pcDNA™3.1 direccional TOPO™ utiliza el vector pcDNA3.1D/V5-His-TOPO™ linealizado y activado por la topoisomerasa I para lograr una clonación direccional en cinco minutos y la posterior expresión de alto nivel.

La tecnología de clonación direccional facilita los experimentos de expresión gracias a las siguientes características:

• Una enzima de corrección utilizada para menos errores en los genes clonados
• Más del 90 % de los clones están en la orientación correcta para la expresión génica, lo que reduce el tiempo dedicado a la detección de colonias.

Además, pcDNA3.1D/V5-His-TOPO™ proporciona fuertes niveles de expresión del promotor del CMV y la opción de una etiqueta C-terminal V5-His Fusion para una fácil detección de la proteína recombinante con un anticuerpo anti-V5 y una rápida purificación en resina quelante de níquel.

Para uso exclusivo en investigación. No apto para uso en procedimientos diagnósticos.

Especificaciones
Sistema constitutivo o inducibleConstitutivo
Tipo de entregaTransfección
Para utilizar con (aplicación)Expresión constitutiva
Tipo de productoKit de expresión TOPO
Cantidad40 reacciones
Agente de selección (eucariótico)Geneticin™ (G-418)
VectorVectores TOPO direccionales, pcDNA
Método de clonaciónTOPO direccional
Línea de productosTOPO, pcDNA
PromotorCMV
Etiqueta de proteínaEtiqueta His (6x), Etiqueta de epítopo V5
Unit SizeEach
Contenido y almacenamiento
2 x Caja 1 (conservar a-20°C):
• 20 μl de pcDNA™3.1D/V5-His-TOPO™ (15–20 ng/μl)
• 10 μl de mezcla dNTP
• 50 μl de solución salina
• 1 ml de agua estéril
• 20 μl de cebador de secuenciación T7 (0.1 μg/μl)
• 20 μl de cebador de secuenciación inversa BGH (0.1 μg/μl)
• 10 μl de muestra de control para PCR (0.1 μg/μl)
• 10 μl de cebadores de control para PCR (0.1 μg/μl cada uno)
• 10 μl de plásmido de control de expresión (0.5 μg/μl)

2 x Caja 2 (conservar a -80°C):
• 6 ml de S.O.C. (puede almacenarse a 4 °C o temperatura ambiente)
• 21 x 50 μl de células TOP10
• 50μl de ADN de control pUC19

Preguntas frecuentes

I performed stable selection but my antibiotic-resistant clones do not express my gene of interest. What could have gone wrong?

Here are possible causes and solutions:

Detection method may not be appropriate or sensitive enough:
- We recommend optimizing the detection protocol or finding more sensitive methods. If the protein is being detected by Coomassie/silver staining, we recommend doing a western blot for increased sensitivity. The presence of endogenous proteins in the lysate may obscure the protein of interest in a Coomassie/silver stain. If available, we recommend using a positive control for the western blot.
- Insufficient number of clones screened: Screen at least 20 clones.
- Inappropriate antibiotic concentration used for stable selection: Make sure the antibiotic kill curve was performed correctly. Since the potency of a given antibiotic depends upon cell type, serum, medium, and culture technique, the dose must be determined each time a stable selection is performed. Even the stable cell lines we offer may be more or less sensitive to the dose we recommend if the medium or serum is significantly different.
- Expression of gene product (even low level) may not be compatible with growth of the cell line: Use an inducible expression system.
- Negative clones may result from preferential linearization at a vector site critical for expression of the gene of interest: Linearize the vector at a site that is not critical for expression, such as within the bacterial resistance marker.

I used a mammalian expression vector but do not get any expression of my protein. Can you help me troubleshoot?

Here are possible causes and solutions:

- Try the control expression that is included in the kit
Possible detection problem:

- Detection of expressed protein may not be possible in a transient transfection, since the transfection efficiency may be too low for detection by methods that assess the entire transfected population. We recommend optimizing the transfection efficiency, doing stable selection, or using methods that permit examination of individual cells. You can also increase the level of expression by changing the promoter or cell type.
- Expression within the cell may be too low for the chosen detection method. We recommend optimizing the detection protocol or finding more sensitive methods. If the protein is being detected by Coomassie/silver staining, we recommend doing a western blot for increased sensitivity. The presence of endogenous proteins in the lysate may obscure the protein of interest in a Coomassie/silver stain. If available, we recommend using a positive control for the western blot. Protein might be degraded or truncated: Check on a Northern. Possible time-course issue: Since the expression of a protein over time will depend upon the nature of the protein, we always recommend doing a time course for expression. A pilot time-course assay will help to determine the optimal window for expression. Possible cloning issues: Verify clones by restriction digestion and/or sequencing.

Find additional tips, troubleshooting help, and resources within our Protein Expression Support Center.

I am using a mammalian expression vector that has the neomycin resistance gene. Can I use neomycin for stable selection in mammalian cells?

No; neomycin is toxic to mammalian cells. We recommend using Geneticin (a.k.a. G418 Sulfate), as it is a less toxic and very effective alternative for selection in mammalian cells.

Is it okay if my construct has an ATG that is upstream of the ATG in my gene of interest? Will it interfere with translation of my gene?

Translation initiation will occur at the first ATG encountered by the ribosome, although in the absence of a Kozak sequence, initiation will be relatively weak. Any insert downstream would express a fusion protein if it is in frame with this initial ATG, but levels of expressed protein are predicted to be low if there is a non-Kozak consensus sequence. If the vector contains a non-Kozak consensus ATG, we recommend that you clone your gene upstream of that ATG and include a Kozak sequence for optimal expression.

What is the difference between pcDNA3.1 vectors and the pcDNA3.3-TOPO vector?

pcDNA3.1 vectors contain the core CMV promoter that is truncated before the start of transcription, whereas the pcDNA 3.3-TOPO vector has the 672 bp native CMV promoter. This native CMV promoter allows high-level gene expression with two- to five-fold higher protein yields compared to other expression vectors. pcDNA3.1 vectors are available in restriction, TOPO, and Gateway cloning versions and as untagged and epitope-tagged versions, whereas the pcDNA3.3-TOPO vector is a TOPO TA-adapted, untagged vector that can be used to express native proteins without extraneous amino acids, and is hence ideal for antibody production and structural biology.

Citations & References (3)

Citations & References
Abstract
Functional analysis of the human papillomavirus type 16 E1=E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization.
Authors:Wang Q, Griffin H, Southern S, Jackson D, Martin A, McIntosh P, Davy C, Masterson PJ, Walker PA, Laskey P, Omary MB, Doorbar J,
Journal:J Virol
PubMed ID:14694114
'High-risk human papillomaviruses, such as human papillomavirus type 16 (HPV16), are the primary cause of cervical cancer. The HPV16 E1=E4 protein associates with keratin intermediate filaments and causes network collapse when expressed in epithelial cells in vitro. Here, we show that keratin association and network reorganization also occur in vivo ... More
Kaposi's sarcoma-associated herpesvirus K8 exon 3 contains three 5'-splice sites and harbors a K8.1 transcription start site.
Authors: Tang Shuang; Zheng Zhi-Ming;
Journal:J Biol Chem
PubMed ID:11832484
Kaposi's sarcoma-associated herpesvirus (KSHV) K8 and K8.1 open reading frames are juxtaposed and span from nucleotide (nt) 74850 to 76695 of the virus genome. A K8 pre-mRNA overlaps the entire K8.1 coding region, and alternative splicing of KSHV K8 and K8.1 pre-mRNAs each produces three isoforms (alpha, beta, and gamma) ... More
Blood group A glycosyltransferase occurring as alleles with high sequence difference is transiently induced during a Nippostrongylus brasiliensis parasite infection.
Authors: Olson Fredrik J; Johansson Malin E V; Klinga-Levan Karin; Bouhours Danièle; Enerbäck Lennart; Hansson Gunnar C; Karlsson Niclas G;
Journal:J Biol Chem
PubMed ID:11842091
Neutral mucin oligosaccharides from the small intestine of control rats and rats infected with the parasite Nippostrongylus brasiliensis were released and analyzed by gas chromatography-mass spectrometry. Infected animals expressed seven blood group A-like structures that were all absent in the control animals. The blood group A nature of these epitopes ... More